Close Menu

The story has been updated to include comments from Vermillion's conference call on Thursday.

NEW YORK (Genomeweb News) – Vermillion reported after the close of the market Thursday that its third quarter revenues were up 3 percent year over year at $330,000 versus $319,000 in Q3 2012.

The company posted product revenue of $216,000, up 5 percent from $205,000 year over year. That revenue was based on 4,328 OVA1 ovarian cancer tests performed in Q3 2013 versus 4,100 tests performed in the year-ago period.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.

A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.

In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."

In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.